{"filing":{"accession_number":"0001213900-26-069873","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295250-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026069873/ea0295250-6k_clearmind.htm"},"events":[{"id":12029,"run_id":10590,"accession_number":"0001213900-26-069873","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Clearmind announced the grant of U.S. Patent No. 12,350,242 for \"Binge Behavior Regulators\" covering its molecule MEAI, bringing its total granted patent portfolio to 32 patents across 19 families. For a clinical-stage biotech company, patent grants are operationally significant milestones that strengthen IP protection for lead candidates like CMND-100 and support competitive positioning in psychedelic-based therapeutics. While not a specific named event type, this is a material operational/strategic disclosure affecting the company's intellectual property position and development pipeline.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8764,"accession_number":"0001213900-26-069873","item_number":"EX-99.1","item_title":"ea029525002ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Clearmind announced the grant of U.S. Patent No. 12,350,242 for \"Binge Behavior Regulators\" covering its molecule MEAI, bringing its total granted patent portfolio to 32 patents across 19 families. For a clinical-stage biotech company, patent grants are operationally significant milestones that strengthen IP protection for lead candidates like CMND-100 and support competitive positioning in psychedelic-based therapeutics. While not a specific named event type, this is a material operational/strategic disclosure affecting the company's intellectual property position and development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:56:41.329429+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8764,"accession_number":"0001213900-26-069873","item_number":"EX-99.1","item_title":"ea029525002ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Clearmind announced the grant of U.S. Patent No. 12,350,242 for \"Binge Behavior Regulators\" covering its molecule MEAI, bringing its total granted patent portfolio to 32 patents across 19 families. For a clinical-stage biotech company, patent grants are operationally significant milestones that strengthen IP protection for lead candidates like CMND-100 and support competitive positioning in psychedelic-based therapeutics. While not a specific named event type, this is a material operational/strategic disclosure affecting the company's intellectual property position and development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:56:41.329429+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-18"}]}